Published in PLoS One on May 09, 2014
HPV vaccination for prevention of skin cancer. Hum Vaccin Immunother (2015) 0.88
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75
Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies. Curr Protoc Microbiol (2015) 0.75
Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions. Mol Ther Methods Clin Dev (2017) 0.75
Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. J Virol (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Classification of papillomaviruses. Virology (2004) 14.16
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J (1991) 4.07
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Human papillomavirus infection requires cell surface heparan sulfate. J Virol (2001) 3.32
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem (1999) 3.16
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37
Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol (1999) 2.35
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol (2006) 2.16
Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol (2001) 2.02
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A (2009) 1.90
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol (2003) 1.82
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst (2011) 1.71
Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem (2007) 1.66
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog (2009) 1.57
Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol (2005) 1.44
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One (2012) 1.38
Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog (2012) 1.36
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol (2001) 1.28
Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic (2012) 1.23
Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers (2007) 1.19
Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem (2010) 1.13
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs (2011) 1.04
Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat Rev Microbiol (2013) 1.04
Heparin increases the infectivity of Human Papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell Microbiol (2013) 1.00
The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther (2011) 0.98
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
Inhibition of gamma secretase blocks HPV infection. Virology (2010) 0.94
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
The impact of preventive HPV vaccination. Discov Med (2006) 0.91
Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS One (2013) 0.91
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine (2009) 0.87
Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism. Virol J (2008) 0.85
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84
Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. J Gen Virol (2013) 0.80
Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology (2013) 0.89
Immunologic Control of Mus musculus Papillomavirus Type 1. PLoS Pathog (2015) 0.83
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79